84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC

Oxbow Advisors LLC acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 84,741 shares of the biopharmaceutical company’s stock, valued at approximately $2,990,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in shares of Royalty Pharma by 367.7% during the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after acquiring an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after purchasing an additional 13,489 shares during the last quarter. Focus Partners Wealth purchased a new position in Royalty Pharma in the 1st quarter worth approximately $264,000. Intech Investment Management LLC grew its stake in Royalty Pharma by 41.0% in the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Royalty Pharma by 23.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 20,201 shares of the biopharmaceutical company’s stock worth $735,000 after buying an additional 3,841 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Insider Activity at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 69,594 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $39.30, for a total transaction of $2,735,044.20. Following the completion of the transaction, the chief financial officer owned 54,760 shares in the company, valued at $2,152,068. This represents a 55.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George W. Lloyd sold 132,426 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $38.34, for a total transaction of $5,077,212.84. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,025,675 shares of company stock worth $40,028,396 over the last three months. Insiders own 18.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on RPRX shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a report on Thursday. Leerink Partners set a $45.00 price target on Royalty Pharma in a research note on Thursday, December 11th. The Goldman Sachs Group began coverage on Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Royalty Pharma Trading Up 0.7%

Shares of NASDAQ RPRX traded up $0.29 during mid-day trading on Friday, hitting $40.40. The stock had a trading volume of 3,533,985 shares, compared to its average volume of 3,202,402. The firm has a market cap of $23.32 billion, a P/E ratio of 30.61, a price-to-earnings-growth ratio of 1.53 and a beta of 0.43. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The business has a 50 day moving average price of $39.35 and a two-hundred day moving average price of $37.55. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The firm had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. On average, equities analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be given a $0.235 dividend. The ex-dividend date is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is 66.67%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.